Objectif CONQUEST aims to commercialise a first-of-its-kind platform technology for imaging a biological effect – i.e. the EPR effect – that is predictive for a cancer patient's response to tumor-targeted nanomedicine (NM) therapy. CONQUEST thereby addresses a key issue in the (nano)pharmaceutical industry; as currently large proportions of cancer patients do not respond to NM, while others show major improvements in terms of response rates, survival times and quality of life. This trend impairs the outcome of clinical studies and results in many patients receiving treatments that are not effective to them. It would therefore be highly desirable to stratify responders from non-responders prior to study entry or treatment. CONQUEST stands at the basis of introducing a solution to this problem in the pharmaceutical industry. Prof. Lammers and colleagues, as part of ERC-funded research, have developed a powerful imaging approach that allows to construct an EPR profile of each individual tumour - by the administration and non-invasive imaging of contrast agent-labelled nanocarriers (drug-loaded or empty) that accumulate in tumours through EPR. The general idea is that patients with a low degree of EPR, and therefore unlikely to respond to such treatments, can be excluded from NM treatment and referred to alternative established or experimental interventions. Vice versa, patients with a high level of EPR can likely be treated relatively efficiently.Recognising the commercial potential of this technology, CONQUEST aims to tailor the technique and protocol for application in humans, by tuning the method for imaging with PET-MRI. A successful demonstration of PET-MRI-based EPR imaging will trigger large interest of the pharmaceutical and diagnostics industry, to invest in further clinical (co-) development. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncology Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-PoC-2015 - ERC Proof of Concept Grant Appel à propositions ERC-2015-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil UNIVERSITAETSKLINIKUM AACHEN Contribution nette de l'UE € 145 312,00 Adresse Pauwelsstrasse 30 52074 Aachen Allemagne Voir sur la carte Région Nordrhein-Westfalen Köln Städteregion Aachen Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 145 312,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire UNIVERSITAETSKLINIKUM AACHEN Allemagne Contribution nette de l'UE € 145 312,00 Adresse Pauwelsstrasse 30 52074 Aachen Voir sur la carte Région Nordrhein-Westfalen Köln Städteregion Aachen Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 145 312,00